Pfizer is betting much of its future on cancer drugs, believing they can earn billions of dollars in sales and turn around a company that has been struggling with falling COVID-19 revenue and lower-price competition, Jared Hopkins of The Wall Street Journal reports. The company’s purchase of Seagen is central to its strategy, for it gained three next-generation cancer therapies on the market and at least a dozen drugs in development.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Applied Materials, H&R Block report quarterly beats: Morning Buzz
- Pfizer, BioNTech provide update on mRNA-based combination vaccine program
- Biden administration announces lower prices for 10 Medicare drugs in 2026
- U.S. to announce prices for drugs in Medicare negotiations, NY Times says
- Oric Pharmaceuticals price target lowered to $15 from $17 at Oppenheimer